Muutke küpsiste eelistusi

E-raamat: Neuroscience of Depression: Genetics, Cell Biology, Neurology, Behavior, and Diet

Edited by , Edited by (Visiting Professor of Perinatal Wellbeing, Institute for Health and Wellbeing, University of Suffolk, Ipswich, UK), Edited by , Edited by (Rosemead Surgery, Maidenhead, Berkshire, UK), Edited by (Professor, Clinical Biochemistry, School of Life Sciences University of)
  • Formaat: PDF+DRM
  • Ilmumisaeg: 05-Mar-2021
  • Kirjastus: Academic Press Inc
  • Keel: eng
  • ISBN-13: 9780128179369
  • Formaat - PDF+DRM
  • Hind: 156,97 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Formaat: PDF+DRM
  • Ilmumisaeg: 05-Mar-2021
  • Kirjastus: Academic Press Inc
  • Keel: eng
  • ISBN-13: 9780128179369

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

The Neuroscience of Depression: Genetics, Cell Biology, Neurology, Behaviour and Diet is a comprehensive reference to the aspects, features and effects of depression. This book provides readers with the behavior and psychopathological effects of depression, linking anxiety, anger and PSTD to depression. Readers are provided with a detailed outline of the genetic aspects of depression including synaptic genes and the genome-wide association studies (GWAS) of depression, followed by a thorough analysis of the neurological and imaging techniques used to study depression. This book also includes three full sections on the various effects of depression, including diet, nutrition and molecular and cellular effects. The Neuroscience of Depression: Genetics, Cell Biology, Neurology, Behaviour and Diet is the only resource for researchers and practitioners studying depression.

  • Features a section on neurological and imaging, including SPECT Neuroimaging
  • Analyzes how diet and nutrition effect depression
  • Examines the molecular and cellular effects of depression
  • Covers genetics of depression
  • Includes more than 250 illustrations and tables
Contributors xvii
Foreword xxiii
Preface xxv
Part I Genetic aspects of depression
1 Epigenetics in depression
3(12)
Piotr Czarny
Katarzyna Bialek
Sylwia Ziolkowska
Monika Talarowska
Tomasz Sliwinski
Introduction
3(1)
DNA methylation
4(1)
Early-life events, DNA methylation, and depression
5(1)
Different gene methylation profiles in depression models
5(1)
Histone modifications
6(1)
Histone acetylation and depression
6(1)
Histone methylation and depression
6(2)
HDAC inhibitors as antidepressants
8(1)
Histone modification associated with gestational stress and gender differences
8(1)
miRNA mechanisms of action
8(1)
mIRNAs and neuroplasticity in depression
9(1)
miRNAs and animal models of depression
9(1)
miRNAs and postmortem brain
9(1)
miRNAs as a peripheral markers of depression
9(1)
Conclusion
10(1)
References
11(4)
2 Genes, depression, and nuclear DNA
15(10)
Xenia Gonda
Peter Petschner
Introduction
15(1)
Heritability of depression
16(1)
Heterogeneity of depression
16(1)
The multifactorial background of depression
16(1)
The candidate gene approach in depression
17(1)
Genome-wide analytical studies (GWAS) in depression
18(1)
Phenotyping of depression in genetic studies
19(1)
Genetic architecture of depression
19(1)
Implications of genetic studies of depression for clinical practice
20(1)
Conclusion
21(1)
References
22(3)
3 Gene expression in depression: Molecular aspects of postpartum depression
25(12)
Anna Landsman
Introduction
25(1)
What is known about PPD etiology?
25(1)
Molecular biology approaches for the study of PPD: The experimental models
26(1)
Genetic factors for PPD: The female reproductive hormones
26(1)
Genetic factors for PPD: The neuropeptides and mood modulators
26(2)
Genetic factors for PPD: The HPA axis
28(1)
Genetic factors for PPD: The immunoinflammatory response
29(1)
Genetic factors for PPD: The microarray studies
29(1)
Genetic factors for PPD: The epigenetics
30(2)
The importance of the molecular markers for the PPD diagnosis
32(1)
References
33(4)
4 Genetics and epigenetics of the SLC6A4 gene in depression
37(10)
Mariana S. Mendonga
Paula M. Mangiavacchi
Alvaro F.L. Rios
Introduction
37(1)
The role of the serotoninergic system in neurodevelopment depression
38(1)
Genetic variations in the serotonin transporter gene and the risk for depression
39(1)
Stress events and epigenetic changes
40(2)
DNA methylation in the SLC6A4 gene and depression
40(1)
miRNA targeting serotonin transporter
41(1)
Histone modifications
42(1)
Perspectives on the SLC6A4 contribution for depression etiology
42(1)
References
43(4)
5 Molecular basis of tryptophan metabolism disorders associated with depression
47(12)
Paulina Wigner
Piotr Gafecki
Tomasz Sliwihski
Introduction
47(1)
Genetic background of disorders of tryptophan metabolism in depression
48(3)
Depression and localization of TRYCATs genes
48(1)
Molecular aspects of TRYCAT enzyme disorders in the course of depression
48(2)
Genetic aspects of neurotransmitter disorders in the course of depression
50(1)
Disorders of tryptophan metabolism and antidepressant therapy
51(1)
Compensatory (anti)inflammatory reflex system in depression
52(1)
Disorders of tryptophan metabolism in the development of postpartum depression
52(2)
Conclusion
54(1)
References
54(5)
6 Metalloproteinases genes and their relationship with depression
59(10)
Monika Sienkiewicz
Michat Seweryn Karbownik
Mateusz Kowalczyk
Edward Kowalczyk
Monika Talarowska
Introduction
59(1)
Overview
59(1)
Structure, history, classification, and regulation
59(1)
Pathophysiological role
60(2)
Pathophysiology of depression
62(2)
Pharmacotherapy
64(1)
Conclusion
65(1)
References
65(4)
7 Linking gene regions jointly with environment and depression
69(10)
Arianna M. Card
Erin B. Ware
Introduction
69(1)
Candidate gene methods in GxE research
69(1)
Gene-region analyses: A primer
70(1)
Selecting gene regions
71(1)
Gene-region analyses in depression research
72(1)
Challenges and future directions
73(1)
References
74(5)
Part II Molecular and cellular effects of depression
8 Linking depression, mRNA translation, and serotonin
79(10)
Emily Arsenault
Aisha Asad Ahmed
Ayeila Daneshmend
Zeynep Jihad-Mohamad
Edna Matta-Camacho
Melissa Nyveld
Fatimeh-Frouh Taghavi-Abkuh
Molly Zhang
Nahum Sonenberg
Jean-Claude Lacaille
Argel Aguilar-Valles
Introduction
79(2)
Major depressive disorder
79(1)
Serotonergic neurotransmission in MDD
80(1)
Selective serotonin reuptake inhibitors (SSRIs)
81(1)
mRNA translation: A central process in regulating gene expression
81(3)
elF4E phosphorylation controls brain inflammation, 5-HT neurotransmission, and depressive symptoms
82(2)
Dysregulated inflammation in MDD
84(1)
Conclusions
85(1)
References
86(3)
9 Changes in cortical gene expression in major depressive disorders: More evidence implicating inflammatory-related pathways in disease etiology
89(12)
Brian Dean
Cortical dysfunction in major depressive disorders
89(1)
Gene x environment interactions in major depressive disorders
89(1)
Cortical gene expression in major depressive disorders
90(1)
Regional changes in cortical gene expression in major depressive disorders
90(1)
Changes in gene expression in the frontopolar cortex
90(4)
Changes in gene expression in the orbitofrontal cortex
94(1)
Changes in gene expression in the dorsolateral prefrontal cortex
94(1)
Changes in gene expression in the ventrolateral prefrontal cortex
95(1)
Changes in gene expression in the cingulated cortex
95(1)
Changes in gene expression in the premotor and primary motor cortices
95(1)
Changes in gene expression in the temporal cortex
95(1)
Changes in gene expression in the pre-visual cortex
96(1)
Summary of changed cortical gene expression in major depressive disorders
96(1)
From transcriptomics to a biology of major depressive disorders
96(2)
Conclusions
98(1)
References
98(3)
10 FKBP5 gene expression as a biomarker for treatment outcome in depression
101(6)
Marcus Ising
Depression--A stress-related mental disorder
101(1)
Role of FKBP5 in stress response regulation and mood disorders
102(1)
FKBP5 gene expression and antidepressant treatment outcome
102(1)
FKBP5 as a promising antidepressant drug target
103(2)
References
105(2)
11 Neuroimaging a cytokine storm by transducing IL-1oc to hippocampal cornu ammonis: COVID-19 SARS-CoV-2
107(12)
Patricia A. Broderick
Steven L. Cofresi
Introduction
107(1)
Main text
108(2)
The BRODERICK PROBE® is a biomedical sensing device
108(1)
Oh! the fever! Distinguishing intense 5-HT/NE signals from IL-1 a and the 5-HT/NE signals for adaptation by the atypical antidepressant, alprazolam
109(1)
How we separated the mechanisms of stress from the mechanisms of depression! Two genetically distinct species were studied
109(1)
Norepinephrine/serotonergic mechanisms in the septohippocampal circuit
110(1)
Interleukins, memory, and the hippocampus
110(1)
The results
110(1)
What were the differences?
110(1)
Nanobiotechnology model: The device and the circuits
110(5)
Acknowledgments
115(1)
References
115(2)
Further reading
117(2)
12 Linking interleukin-6 and depression
119(8)
Manivel Rengasamy
Rebecca B. Price
Introduction
119(1)
Interlinking interleukin-6 and depression
119(1)
Historical background
119(1)
Review of IL-6 function
120(1)
Preclinical studies
120(1)
Clinical studies of immune system disorders or immunoactive treatments
121(1)
Clinical studies of patients with MDD or other depressive disorders
121(1)
Clinical treatments involving blockade of IL-6 activity
122(1)
Mechanisms of interaction of IL-6 and depression
122(1)
Limitations
122(1)
Future areas of research
123(1)
Conclusion
123(1)
References
123(4)
13 The role of inflammatory signaling in comorbid depression and epilepsy
127(12)
Jana Dimitrova Tchekalarova
Dimitrinka Atanasova
Nikolai Lazarov
Introduction
127(1)
Inflammation in depression and epilepsy
128(1)
The cytokine hypothesis
128(1)
The activated hypothalamic-pituitary-adrenal axis
129(1)
Gliosis
129(1)
The role of inflammation in epilepsy and depression comorbidity
129(3)
The cytokine hypothesis
129(2)
Hyperactivity of HPA axis
131(1)
Activated microglia and astrocytes
131(1)
Others
132(1)
Conclusions
132(3)
References
135(4)
14 Brain inflammasomes in depression
139(10)
Stefanie Hoffmann
Cordian Beyer
Introduction
139(1)
Inflammasomes, structure-function relationship and role in brain diseases
140(1)
Major depressive disorders
141(1)
Linking depressive disorders to neuroinflammation
142(1)
Inflammasomes are key players in MDD
143(1)
Conclusion
144(1)
References
144(5)
15 Inflammatory factors and depression in substance use disorder
149(12)
Maria Flores-Lopez
Oscar Porras-Perales
Nerea Requena-Ocana
Nuria Garcfa-Marchena
Pedro Araos
Antonia Serrano
Manuel Jimenez-Navarro
Fernando Rodriguez de Fonseca
Francisco Javier Pavon
Introduction
149(1)
Substance use disorder
150(2)
Definition
150(1)
Neurobiology
150(1)
Vulnerability
151(1)
Health consequences of substance use disorder
152(1)
Comorbidity: Substance use disorder and depression
152(2)
Primary and substance-induced depression
152(1)
Dopamine a link between substance use disorder and depression in the brain
153(1)
Inflammation in substance use disorder and depression
154(3)
NF-kB pathway and release of proinflammatory factors
154(2)
Inflammation in the periphery and neuroendocrine pathways
156(1)
Neuroinflammation and effects on neurotransmission
157(1)
Conclusions and identification of inflammatory biomarkers
157(2)
References
159(2)
16 Linking Huntington disease, brain-derived, neurotrophic factor, and depressive-like behaviors
161(18)
Evelini Placido
Cristine de Paula Nascimento-Castro
Priscilla Gomes Welter
Joana Gil-Mohapel
Patricia S. Brocardo
Huntington's disease
161(1)
Motor dysfunction
161(1)
Cognitive alterations
162(1)
Neuropsychiatric features
162(1)
Brain-derived neurotrophic factor
162(1)
The role of brain-derived neurotrophic factor in depression
163(1)
Alterations of brain-derived neurotrophic factor signaling in HD
163(5)
Relationship between brain-derived neurotrophic factor and huntingtin
163(1)
BDNF deficits in HD animal models
163(5)
BDNF deficits in HD patients
168(1)
Depression in HD: A putative role for brain-derived neurotrophic factor
168(4)
Relationship between BDNF levels and depression in HD
168(1)
Protective effects of BDNF expression in HD mouse models
168(4)
Conclusions
172(1)
References
173(6)
17 Depression and the NMDA receptor/NO/cGMP pathway
179(10)
Joao Ronielly Campelo Araujo
Ana Cristina de Oliveira Monteiro-Moreira
Introduction
179(1)
The glutamatergic system and the L-arginine/NO/cGMP pathway
180(1)
NMDA receptor/NO/cGMP pathway as therapeutic target for depression
181(1)
NMDA receptor antagonists
182(1)
Broad glutamatergic modulators
182(1)
NR2B subunit NMDA-selective antagonist
183(1)
L-arginine/NO/cGMP pathway inhibitors
183(1)
Prospects and future directions
183(1)
Conclusion
184(1)
References
185(4)
18 Translocator protein (18 kDaTSPO) binding in depression
189(8)
Szabolcs Keri
Introduction: The inflammatory theory of depression
189(1)
Postmortem studies and central markers of inflammation
189(1)
The translocator protein: A putative marker of neuroinflammation
190(1)
In vivo imaging of neuroinflammation in MDD: Initial findings, controversies, and clinical implications
190(1)
TSPO binding and cognitive functions in depression
191(1)
TSPO binding and response to psychotherapy
192(1)
Limitations and future directions
193(2)
References
195(2)
19 Axonal transport proteins: What they are and how they relate to depressive behaviors
197(18)
Arezo Nahavandi
Soraya Mehrabi
What is axonal transport?
197(2)
Kinesin
199(1)
Dynein
199(1)
Axonal transport and brain function
199(7)
The mRNA and cytosolic proteins
199(1)
The neurotrophin distribution
199(5)
The vesicular transport
204(1)
Mitochondrial axonal transport
204(1)
Plasticity and synaptogenesis
205(1)
Axonal elongation
206(1)
Axonal transport proteins and neuroinflammation
206(1)
Axonal transport proteins and neurodegeneration
207(1)
Axonal transport proteins and depressive-like behavior
207(2)
Biogenic monoamines
207(1)
Genetic modulation
208(1)
Stress
208(1)
Environmental enrichment
208(1)
The neurodegenerative conditions
208(1)
Synaptic transmission
208(1)
Synaptogenesis
208(1)
Axonal guidance
208(1)
Neurogenesis
209(1)
Glucocorticoids and their receptors
209(1)
Conclusion
209(1)
References
210(5)
20 Molecular features of adenylyl cyclase isoforms and cAMP signaling: A link between adenylyl cyclise 7 and depression
215(10)
Gianna Giacoletti
Abdulwhab Shremo Msdi
Ryan Cook
Tarsis F. Brust
Introduction
215(1)
Overview of adenylyl cyclases
215(1)
cAMP signaling and depression
216(3)
Adenylyl cyclase 7
219(1)
Adenylyl cyclise 7 and depression
219(2)
Conclusions
221(1)
Acknowledgments
221(1)
References
222(3)
21 Neurobiology of depression: The role of glycogen synthase kinase 3
225(10)
Minal Sonawane
Giuseppe Aceto
Jessica Di Re
Marcello D'Ascenzo
Thomas A. Green
Fernanda Laezza
Introduction
225(1)
Posttranslational mechanisms regulating GSK3 activity
225(1)
GSK3|S in mood disorders and depression
226(1)
GSK3 and experimental models of depression-like behaviors
226(1)
Role of GSK3 in regulating intrinsic excitability
227(1)
GSK3 and voltage-gated sodium (Nav) channels
227(1)
GSK3 and accessory proteins of the voltage-gated sodium (Nav) channel complex
227(1)
GSK3 phosphorylation of the voltage-gated sodium (Nav) channel in experimental models of vulnerability to depression-like behavior
228(1)
GSK3 and voltage-gated potassium (Kv) channels
228(1)
Functional implications of GSK-3-dependent Kv4.2 phosphorylation
229(1)
GSK3 and Kv channels in experimental models of depression-like behaviors
229(1)
Conclusions
229(3)
References
232(3)
22 Sortilin/neurotensin receptor-3 and its derived peptides in depression
235(8)
Jean Mazella
Marc Borsotto
Catherine Heurteaux
Introduction
235(1)
How TREK-1 became a target in depression
236(1)
How sortilin was shown to be involved in depression
236(1)
Spadin and spadin analogs are selective fast-acting antidepressants
237(1)
Posttranslational products of NTSR3/sortilin as biomarkers
238(1)
The role of spadin as a link between obesity/diabetes and depression
238(1)
Conclusions
238(1)
References
239(4)
23 Implication of Wnt/beta-catenin signaling and its components in depression and neuropsychiatric disorders
243(12)
Akanksha Mishra
Sonu Singh
Shubha Shukla
Introduction
243(1)
The canonical Wnt signaling pathway
244(1)
Noncanonical Wnt signaling pathway
244(1)
Wnt/Ca+2 pathway
244(1)
Wnt/PCP pathway
244(1)
Wnt/p-catenin signaling components in depression
244(2)
Disheveled
246(1)
GSK-3p"
247(1)
Wnts
248(1)
Frizzled
248(1)
Crosstalk between neurogenesis and Wnt signaling in depression and psychiatric disorders
249(1)
Antidepressants utilize Wnt signaling and its components for the action
250(1)
Concluding remarks
251(1)
References
252(3)
24 The prefrontal cortex in depression: Use of proteomics
255(12)
Gaborjuhasz
Vanda Tukacs
Daniel Mittli
Katalin Adrienna Kekesi
Introduction
255(1)
OMICS allowed a new insight into neuronal phenotype
256(1)
The basics of proteomic studies
257(1)
Proteomic studies in depression research
258(1)
Proteome changes in depression
258(3)
Limitations and perspectives
261(1)
References
262(5)
Part III Neurological and imaging features
25 How brain single photon emission computed topography imaging informs the diagnosis and treatment of mood disorders
267(10)
Daniel Amen
Jay Faber
Muneer Ali
Nelson Bennett
Rishi Sood
Mona Karimpour
Introduction
267(1)
Imaging does not match the DSM, but can enhance it
268(1)
Brain SPECT imaging
268(1)
SPECT mood disorder literature
269(1)
Hypofrontality
269(1)
Hyperfrontality
269(1)
Overall decreased perfusion
270(1)
Brain trauma
271(1)
Cognitive disorders vs depression
271(1)
How SPECT changes clinical practice and may improve outcomes
272(1)
SPECT, mood disorders, and treatment response
272(1)
References
273(4)
26 Resting-state functional magnetic resonance imaging (rsfMRI) in bipolar and unipolar depression
277(24)
Kristen K. Ellard
Sofia Uribe
Christopher J. Funes
Introduction
277(1)
A framework for synthesizing rsfMRI results: Distributed functional networks
277(1)
Resting-state functional connectivity in unipolar depression
278(9)
Default mode network connectivity
278(8)
Salience network functional connectivity
286(1)
Resting-state functional connectivity in bipolar depression
287(7)
Default mode network connectivity
287(5)
Salience network connectivity
292(2)
Somatomotor network connectivity
294(1)
Functional connectivity differences between unipolar and bipolar depression
294(2)
Challenges to interpretation of resting-state studies
296(1)
Future directions
296(1)
References
297(4)
27 Linking amygdala blood oxygenation-level-dependent (BOLD) activity and frontal EEC in depression
301(10)
Vadim Zotev
Jerzy Bodurka
Introduction
301(1)
Emotion regulation system
301(1)
Emotion regulation in depression
302(1)
Frontal EEC asymmetry and depression
302(1)
Linking amygdala BOLD activity and frontal EEC
303(1)
Amygdala real-time fMRI neurofeedback with simultaneous EEG
303(1)
EEG activity during the real-time fMRI neurofeedback procedure
304(1)
Frontal EEG asymmetry changes and depression severity
305(1)
EEG coherence enhancement and depression severity
306(1)
Correlations of amygdala BOLD activity and frontal EEG asymmetry
306(1)
Conclusion
307(2)
References
309(2)
28 The rostromedial tegmental nucleus: Features and links with alcohol and depression
311(12)
Qi Kang Zuo
Wanhong Zuo
Jean Daniel Eloy
Jiang-Hong Ye
Background
311(1)
RMTg: Characteristics, inputs, and outputs associated with alcohol and depression
312(3)
RMTg afferents: Alcohol and depression
313(1)
RMTg efferents: Alcohol and depression
314(1)
RMTg activity in alcohol consumption and depression
315(3)
RMTg activity and alcohol use
315(1)
RMTg activity and depression
315(3)
Role of the RMTg in alcohol withdrawal-induced negative affect
318(1)
Conclusion
319(1)
References
319(4)
29 Human serotonergic neurons, selective serotonin reuptake inhibitor (SSRI) resistance and major depressive disorder
323(8)
Krishna C. Vadodaria
Kelly J. Heard
Fred H. Gage
Introduction
323(1)
IPSC reprogramming
324(1)
Generating human serotonergic neurons
324(2)
Studying serotonergic neurotransmission in patient serotonergic neurons
326(2)
Studying serotonergic neurotransmission in patient cortical neurons
328(1)
Limitations in iPSC work
328(1)
References
329(1)
Further reading
330(1)
30 Role of nesfatin-1 in major depression
331(10)
Ece Turkyilmaz Uyar
Efruz Pirdogan Aydin
Introduction
331(1)
Structure and distribution of NUCB protein family
331(1)
Molecular structure of nesfatin-1
332(1)
Distribution and effects of nesfatin-1
333(1)
Nesfatin-1 and psychiatric disorders
334(1)
Nesfatin-1 and depression
334(4)
References
338(3)
31 Impact of NGF signaling on neuroplasticity during depression: Insights in neuroplasticity-dependent therapeutic approaches
341(10)
Mir Hilal Ahmad
M. Moshahid Azam Rizvi
Mahino Fatima
Amal Chandra Mondal
Introduction
341(1)
Changes in neuroplasticity during the pathophysiology of depression
342(1)
Neuronal plasticity: Growth and change in depression
342(1)
NGF and neuroplasticity: The evidence
342(1)
Role of NGF in the plasticity of hippocampal and basal forebrain cholinergic neurons
342(1)
NGF dysregulation in depression
343(1)
Clinical evidence
343(1)
Preclinical evidence
343(1)
NGF regulation in antidepressants treatment
343(2)
New perspectives for refining future treatment approaches: Neuroplasticity-dependent therapeutic approaches
345(1)
Concluding remarks
345(3)
Acknowledgments
348(1)
References
348(3)
32 Inherited depression and psychological disorders and mental illness by germ cells and their memory
351(10)
Amani Ahmed
Muaweah Ahmad Alsaleh
Introduction
351(1)
Psychiatric pathologies
351(1)
Depression and degradation of germ cells
351(1)
Genetic memory
351(1)
Do the same causes produce the same effects in humans?
352(1)
Wartime, depression, and germ cells
352(1)
Psychological and environmental factors and female-male germ cells-fertility
352(1)
Transmission of trauma via germ cells
352(1)
Reverse process
353(1)
Exercise, nutritional status, seasonal variations, and germ cells
353(1)
What is happening inside and beyond the uterus?
353(1)
Psychotherapy and sexual behavior
353(1)
Cognitive/physical activities and sexual behavior
354(1)
Relaxation and music/dance therapy
354(1)
Discussion
354(1)
Conclusion
355(1)
Disclosure of potential conflicts of interest
356(1)
References
356(5)
Part IV Behaviour and psychopathological effects
33 Cognitive function and neurocognitive deficits in depression
361(12)
Maria Semkovska
The "hot" and "cold" cognitive processes in depression
361(1)
Cognitive predictors of depression
362(1)
Hot cognition
362(1)
Cold cognition
362(1)
The "trait" hypothesis
363(1)
Cognitive function associated with a depressive episode
363(1)
Hot cognition
363(1)
Cold cognition
364(1)
The "state" hypothesis
364(1)
Cognitive function following depressive episode remission
364(3)
Hot cognition
364(2)
Cold cognition
366(1)
The "scar" hypothesis
367(1)
Conclusion and future directions
367(2)
References
369(4)
34 Cognitive and interpersonal contributors to relationship distress and depression: A review of the dyadic partner-schema model
373(8)
Jesse Lee Wilde
Jennifer C.P. Gillies
David J.A. Dozois
Introduction
373(1)
An overview of the dyadic partner-schema model
373(4)
Partner-schemas are key contributors to ongoing cognitions and behaviors toward romantic partners
374(1)
Depressive behaviors occur within a dyadic context
375(1)
Dysfunctional dyadic interactions impact present and future relationship distress and depression
376(1)
There is a reciprocal relationship between distress and depression
376(1)
Self- and partner-schema structures become consolidated over time as a result of negative partner interactions
377(1)
Clinical implications of the dyadic partner-schema model
377(1)
Directions for future research
378(1)
Conclusion
378(1)
Acknowledgment
379(1)
References
379(2)
35 Cognitive vulnerability to depression in adolescence
381(8)
Richard T. Liu
Jessica L. Hamilton
Alexandra H. Bettis
Introduction
381(1)
Developmental antecedents to cognitive vulnerability to depression
381(1)
Childhood maltreatment and cognitive vulnerability to depression
382(1)
Peer victimization and cognitive vulnerability to depression
382(1)
Limitations of the research on early life influences of cognitive vulnerability to depression
383(1)
Neurobiological findings for early life adversities
383(1)
Neurobiological findings for cognitive vulnerability to depression
383(1)
Conclusion and future directions
384(1)
References
385(4)
36 Determining the cognitive performance in the first episode of depression
389(8)
Muriel Vicent-Gil
Maria J. Portella
Introduction
389(1)
Cognitive dysfunction in MDD
389(1)
A brief history of cognitive dysfunction in MDD
390(1)
Impact of cognitive dysfunction in MDD
390(1)
Cognitive dysfunction in the first episode of MDD
391(2)
Previous research
391(2)
Recent approach
393(1)
Conclusions
393(2)
References
395(2)
37 Body image and depression
397(8)
Paivi Pylvanainen (Maria)
Anita Forsblom
Joona Muotka
Katriina Hyvonen
Introduction
397(1)
Tripartite model of body image
397(1)
Reciprocal shaping: Body image is shaped by interaction and body image shapes interaction
398(1)
Systems view: The neurological layers of embodiment
398(1)
Body image assessment
399(1)
Studies of the body image in patients with depression
399(1)
Discomfort in sensing the body
400(1)
Body memory contents of the depressed patients' body image
400(1)
Body image quality and recovery from depression
401(1)
Addressing and accepting body image contents in the treatment ctf depression
401(1)
Dance movement therapy in the treatment of patients with depression
402(1)
References
403(2)
38 Sleep, anxiety, and depression
405(10)
Li-Ting Huang
Kelly L. Sullivan
Introduction
405(1)
Fundamentals of sleep
405(1)
Sleep architecture
406(1)
Insomnia
406(1)
Available treatments for insomnia
407(2)
Anxiety disorders
409(1)
Treatments for anxiety disorders
409(2)
Mechanisms of sleep, anxiety, and depression
411(1)
Conclusion
411(1)
References
412(3)
39 Depression, anxiety, and quality of life
415(10)
Kerning Gao
Jian Zhang
Introduction
415(1)
Measures of qualify of life
415(1)
Depression and quality of life
416(2)
MDD and bipolar depression
416(1)
MDD vs bipolar depression
416(1)
Depression comorbid with other psychiatric disorders
416(1)
Depression with medical conditions
416(2)
Effect of treatment for depression on quality of life
418(1)
Pharmacological treatments for MDD and bipolar depression
418(1)
Psychotherapy
418(1)
Antidepressant plus psychotherapy
418(1)
Electroconvulsive therapy
418(1)
Depression in medical conditions
419(1)
Anxiety and quality of life
419(2)
Generalized anxiety disorder
419(1)
Panic disorder
419(1)
Social anxiety disorder
420(1)
Anxiety with medical conditions
421(1)
Effect of treatment for anxiety on quality of life
421(1)
Pharmacological treatments
421(1)
Psychotherapy
421(1)
Anxiety in medical conditions
421(1)
Conclusions
421(1)
References
422(3)
40 Reward processing and depression: Current findings and future directions
425(10)
Daniel M. Mackin
Brady D. Nelson
Daniel N. Klein
Introduction
425(1)
Theory linking reward processing and depression
425(2)
Reward processing and depression: A review of behavioral studies
427(1)
An ERP measure of reward processing
427(1)
Reward processing and depression: A review of ERP studies
427(1)
fMRI measurement of reward processing
428(1)
Reward processing and depression: A review of fMRI studies
429(1)
Life stress, reward processing, and depression
430(1)
Conclusion and future directions
430(2)
References
432(3)
41 Sexual functioning in depression
435(18)
Sandeep Grover
Swapnajeet Sahoo
Introduction
435(1)
The problem statement: Sexual dysfunction in depressed individuals
435(1)
Pathophysiology of sexual dysfunction in depression
436(1)
Incidence and pathophysiology of TESD/antidepressant-induced sexual dysfunction
436(1)
Impact of sexual dysfunction on depression
437(1)
Risk factors for developing sexual dysfunction during antidepressant therapy
437(1)
Assessment of sexual functioning in patients with depression
437(4)
Management of sexual dysfunctions in depression
441(4)
Conclusions
445(1)
References
445(8)
Part V Diet, nutrition and botanicals
42 Linking dietary glycemic index and depression
453(10)
Sima Jafarirad
Mehran Rahimlou
Introduction
453(1)
Carbohydrates and glycemic index
453(1)
Glycemic responses and depression
454(1)
Observational studies
455(3)
Clinical trials
458(1)
Possible mechanisms
458(1)
Conclusion
458(2)
References
460(3)
43 Gut microbiota and depression
463(10)
Asma Kazemi
Kurosh Djafarian
Introduction
463(1)
Gut microbiota and brain communication
463(3)
Effect of stress and depression on gut microbiota
464(1)
Effect of gut microbiota on depressive disorder
464(1)
Effect of changes in gut microbiota on depression (animal studies)
465(1)
Association between gut microbiota and depression (human studies)
465(1)
The mechanisms of action
466(4)
References
470(3)
44 Linking dietary methyl donors, maternal separation, and depression
473(12)
Mirian Sanblas
Xabier Bengoetxea
Fermin Milagro
Maria J. Ramirez
Introduction
473(1)
Experimental models of depression based on stress in perinatal life
473(3)
Biological background
473(1)
Maternal separation and prenatal stress
474(1)
Epigenetic mechanisms in the context of depression
474(2)
Methyl donors and depression
476(2)
Folate
477(1)
Choline
477(1)
Betaine
478(1)
Vitamin B12
478(1)
Vitamin B6
478(1)
Mutations related to depression in genes of one-carbon metabolism
478(1)
Conclusion
479(2)
References
481(4)
45 Convolvulus pluricaulis usage and depression
485(8)
Priyank Shah
Girdhari Lai Gupta
Introduction
485(1)
Pathology
485(1)
Monoamine transmission
485(1)
Neuroendocrine mechanism
486(1)
Inflammation
486(1)
Reduced neurogenesis and neuroplasticity
486(1)
KEAP1-NRF2 pathway
486(1)
Current synthetic treatment for depression
486(1)
Introduction to herbal medicines
487(1)
Convolvulus pluricaulis
487(1)
Scientific classification
487(1)
Description
488(1)
Pharmacological activities of C. pluricaulis
488(1)
Effect of C. pluricaulis extract (CPE) in the mouse forced swim and tail suspension tests
488(2)
Effect of C. pluricaulis extract (CPE) behavior induced by chronic unpredictable mild stress in rat
490(1)
Effect of C. pluricaulis against H2O2-induced neurotoxicity in SH-SY5Y human neuronal cells
490(1)
Effect of scopoletin, phytochemical constituent of C. pluricaulis in tail suspension tests
490(1)
Effect of Kaempferol, a phytochemical constituent of C. pluricaulis in TST and FST
490(1)
Conclusion
490(1)
References
491(2)
46 Antidepressant activity of Crocus sativus L. and its main constituents: A review
493(10)
Bibi Marjan Razavi
Azar Hosseini
Hossein Hosseinzadeh
Introduction
493(1)
Antidepressant activity of saffron
493(4)
Animal studies
493(1)
Clinical studies
494(3)
Antidepressant activity of saffron constituents and its bioactive fractions
497(1)
Crocin
497(1)
Crocetin
498(1)
Safranal
498(1)
Kaempferol
498(1)
Bioactive fractions of C. sativus L.
498(1)
Conclusion
499(1)
References
500(3)
47 Mechanisms of action of herbal antidepressants
503(16)
Mahboobeh Ghasemzadeh Rahbardar
Hossein Hosseinzadeh
Introduction
503(1)
Herbal antidepressants
504(10)
Asparagus racemosus (Satawari)
505(1)
Bacopa monnieri (Brahmi)
505(1)
Berberis aristata (Indian Barberry)
505(1)
Camellia sinensis (Tea plant)
505(1)
Cimicifuga racemosa L. (Black Cohosh)
506(1)
Crocus sativus (Saffron)
507(1)
Curcuma longa (Turmeric)
508(1)
Epimedium brevicornum (Bishop's hat)
508(1)
Ginkgo biloba (Ginkgo)
508(1)
Glycyrrhiza glabra L. (Licorice)
508(2)
Hordeum vulgare L. (Barley)
510(1)
Hypericum perforatum (St. John's Wort)
510(1)
Magnolia officinalis (Magnolia bark)
510(1)
Mitragyna speciosa (Kratom)
510(1)
Morinda officinalis (Indian mulberry)
510(1)
Paeonia lactiflora Pall (Garden peony)
510(1)
Polygalasa bulosa (Timutu-pinheirinho)
511(1)
Rhodiola rosea (Roseroot)
512(1)
Rosmarinus officinalis L. (Rosemary)
512(1)
Schinus molle (Peruvian pepper)
512(1)
Siphocampylus verticillatus (Siphocampylus)
512(1)
Tabebuia avellanedae (Pink Tabebuia)
513(1)
Tinospora cordifolia (Guduchi)
514(1)
Zingiber officinale (G i nger)
514(1)
Conclusion
514(1)
References
515(4)
48 Antidepressant-like effects and mechanisms of the herbal formula Xiaochaihutang in depression
519(12)
Kuo Zhang
Jingyu Yang
Chunfu Wu
Introduction
519(1)
Effects of XCHT on depressive animal models
520(2)
Effects of XCHT on CUMS rats
520(1)
Effects of XCHT on CSIS mice
520(1)
Effects of XCHT on CORT mice
521(1)
Effects of XCHT on OVX-CUMS mice
521(1)
Antidepressant mechanisms of XCHT
522(3)
Neurotransmitter
522(1)
Neurotrophic factors
522(1)
Neurogenesis
523(1)
Neuroendocrine
524(1)
Conclusion
525(2)
References
527(4)
Part VI Resources
49 Recommended resources on the neuroscience of depression: Genetics, cell biology, neurology, behavior, and diet
531(8)
Rajkumar Rajendram
Vinood B. Patel
Victor R. Preedy
Introduction
531(1)
Resources
531(6)
Acknowledgments
537(1)
References
537(2)
Index 539
Colin R. Martin RN, BSc, MSc, PhD, MBA, YCAP, FHEA, C.Psychol, AFBPsS, C.Sci is Professor of Clinical Psychobiology and Applied Psychoneuroimmunology and Clinical Director of the Institute of Health and Wellbeing at the University of Suffolk, UK. He is a Chartered Health Psychologist and a Chartered Scientist. He also trained in analytical biochemistry, this aspect reflecting the psychobiological focus of much of his research within mental health. He has published or has in press well over 300 research papers and book chapters. He is a keen book author and editor having written and/or edited more than 50 books. These outputs include the prophetic insight into the treatment of neurological disease, Handbook of Behavior, Food and Nutrition (2011), Nanomedicine and the Nervous System (2012), Oxidative Stress and Dietary Antioxidants in Neurological Disease (2020), Zika Virus Impact, Diagnosis, Control and Models (2021), Factors Affecting Neurodevelopment: Genetics, Neurology, Behavior and Diet (2021), Diagnosis and Treatment of Spinal Cord Injury (2022), The Neurobiology, Physiology, and Psychology of Pain (2022) and The Handbook of Lifespan Cognitive Behavioral Therapy: Childhood, Adolescence, Pregnancy, Adulthood, and Aging (2023). Professor Martin is particularly interested in all aspects of the relationship between underlying physiological substrates and behavior, particularly in how these relationships manifest in both acute and chronic psychiatric disorder. He has published original research germane to significant mental health disorders including the areas of schizophrenia, anxiety, depression, self-esteem, alcohol and drug dependency, high secure forensic mental health and personality disorder. He has a keen interest in the impact of postviral illness and is actively involved in clinical research post-Covid pandemic and in particular, the impact of Long Covid on psychological, neurological, physiological and social functioning. He is involved in collaborative International research with many European and Non-European countries. Dr Lan-Anh Hunter BSc MBBS DFFP DRCOG MRCGP qualified from Guys, Kings & St. Thomas Medical School, London in 2001, where she developed an early interest in psychological medicine. She went on to study culture bound syndromes, whilst reading Medical Anthropology Honours degree at University College London, focusing on the cultural aspects of anorexia nervosa in her thesis. She subsequently worked in Australia and explored the psychological aspects of diabetes and its many complications on the aboriginal population. Prior to becoming a GP Principal, she lectured at Charing Cross Hospital teaching doctors in training, continuing this passion, as a GP trainer in her current role. Much has been written about depression in primary care and hence her call to this area. She specialises in psychological medicine, with training in coaching, narrative based medicine, cognitive behaviour therapy and she continues to see, support, treat and manage clinical depression on an everyday basis as a family GP in her Maidenhead practice. Vinood B. Patel, BSc, PhD, FRSC, is currently Professor in Clinical Biochemistry at the University of Westminster. In 2014 Dr Patel was elected as a Fellow to The Royal Society of Chemistry. Dr Patel graduated from the University of Portsmouth with a degree in Pharmacology and completed his PhD in protein metabolism from Kings College London in 1997. His postdoctoral work was carried out at Wake Forest University Baptist Medical School, NC, USA studying structural-functional alterations to mitochondrial ribosomes, where he developed novel techniques to characterize their biophysical properties. Research is being undertaken to study the role of nutrients, antioxidants, phytochemicals, iron, alcohol and fatty acids in the pathophysiology of liver disease. Other areas of interest are identifying new biomarkers that can be used for the diagnosis and prognosis of disease and understanding mitochondrial oxidative stress in neurological disorders and iron dysregulation in diabetes. Dr Patel is a nationally and internationally recognized researcher and has several edited biomedical books related to the use or investigation of active agents or components. These books include The Handbook of Nutrition, Diet, and Epigenetics, Branched Chain Amino Acids in Clinical Nutrition, Cancer: Oxidative Stress and Dietary Antioxidants, Toxicology: Oxidative Stress and Dietary Antioxidants, Molecular Nutrition: Vitamins, The Neuroscience of Pain, Cognitive Behavioural Therapy. He is Editor of the ten-volume series Biomarkers in Disease: Methods, Discoveries and Applications. Victor R. Preedy BSc, PhD, DSc, FRSB, FRSPH, FRSC, FRCPath graduated with an Honours Degree in Biology and Physiology with Pharmacology. After gaining his University of London PhD, he received his Membership of the Royal College of Pathologists. He was later awarded his second doctorate (DSc), for his contribution to protein metabolism in health and disease. He is Professor of Clinical Biochemistry (Hon) at Kings College Hospital and Emeritus Professor of Nutritional Biochemistry at Kings College London. He has Honorary Professorships at the University of Hull, and the University of Suffolk. Professor Preedy was the Founding Director and then long-term Director of the Genomics Centre at Kings College London from 2006 to 2020. Professor Preedy has been awarded fellowships of the Royal Society of Biology, the Royal College of Pathologists, the Royal Society for the Promotion of Health, the Royal Institute of Public Health, the Royal Society for Public Health, the Royal Society of Chemistry and the Royal Society of Medicine. He carried out research when attached to the National Heart Hospital (part of Imperial College London), The School of Pharmacy (now part of University College London) and the MRC Centre at Northwick Park Hospital. He has collaborated with international research groups in Finland, Japan, Australia, USA, and Germany. To his credit, Professor Preedy has published over 750 articles, which includes peer-reviewed manuscripts based on original research, abstracts and symposium presentations, reviews and edited books. Dr Rajkumar Rajendram is a clinician scientist with a focus on internal medicine, anaesthesia, intensive care and peri-operative medicine. He graduated with distinctions from Guys, Kings and St. Thomas Medical School, Kings College London in 2001. As an undergraduate he was awarded several prizes, merits and distinctions in pre-clinical and clinical subjects.

Dr Rajendram began his post-graduate medical training in general medicine and intensive care in Oxford. He attained membership of the Royal College of Physicians (MRCP) in 2004 and completed specialist training in acute and general medicine in Oxford in 2010. Dr Rajendram subsequently practiced as a Consultant in Acute General Medicine at the John Radcliffe Hospital, Oxford.



Dr Rajendram also trained in anaesthesia and intensive care in London and was awarded a fellowship of the Royal College of Anaesthetists (FRCA) in 2009. He completed advanced training in regional anaesthesia and intensive care. He was awarded a fellowship of the Faculty of Intensive Care Medicine (FFICM) in 2013 and obtained the European diploma of intensive care medicine (EDIC) in 2014. He then moved to the Royal Free London Hospitals as a Consultant in Intensive Care, Anaesthesia and Peri-operative Medicine. He has been a fellow of the Royal College of Physicians of Edinburgh (FRCP Edin) and the Royal College of Physicians of London (FRCP Lond) since 2017 and 2019 respectively. He is currently a Consultant in Internal Medicine at King Abdulaziz Medical City, National Guard Heath Affairs, Riyadh, Saudi Arabia.

Dr Rajendrams focus on improving outcomes from Coronavirus Disease 2019 (COVID-19) has involved research on point of care ultrasound and phenotypes of COVID-19. Dr Rajendram also recognises that nutritional support is a fundamental aspect of medical care. This is particularly important for patients with COVID-19. As a clinician scientist he has therefore devoted significant time and effort into nutritional science research and education. He is an affiliated member of the Nutritional Sciences Research Division of Kings College London and has published over 400 textbook chapters, review articles, peer-reviewed papers and abstracts.